var data={"title":"Poliovirus vaccine (inactivated): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Poliovirus vaccine (inactivated): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6796?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=poliovirus-vaccine-inactivated-drug-information\" class=\"drug drug_general\">see &quot;Poliovirus vaccine (inactivated): Drug information&quot;</a> and <a href=\"topic.htm?path=poliovirus-vaccine-inactivated-patient-drug-information\" class=\"drug drug_patient\">see &quot;Poliovirus vaccine (inactivated): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211024\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>IPOL</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211025\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Imovax Polio</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061202\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Inactivated Virus</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061195\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=poliovirus-vaccine-inactivated-drug-information\" class=\"drug drug_general\">see &quot;Poliovirus vaccine (inactivated): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered &le;4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Use of the minimum age and minimum intervals (4 weeks) during the first 6 months of life should only be done when the vaccine recipient is at risk for imminent exposure to circulating poliovirus (shorter intervals and earlier start dates may lead to lower seroconversion) (CDC/ACIP 2009). Refer to CDC/ACIP for guidance on schedules and interval for individuals who received polio vaccination(s) outside of the US (CDC/ACIP [Marin 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary immunization:</b> Infants and Children 6 weeks to 47 months: IM, SubQ: 0.5 mL per dose for a total of 3 doses administered as follows: 2 months, 4 months, and 6 to 18 months of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Booster immunization:</b> Children 4 to 6 years: IM, SubQ: 0.5 mL as a single dose; administered at least 6 months from the previous dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catch-up immunization</b> (ACIP [Robinson 2016]): Infants, Children, and Adolescents 4 months to 18 years: <b>Note:</b> Do not restart the series if doses have been given (OPV and/or IPV) refer to current immunization guidelines for specific schedule and timing of dose based on patient age and previous number of doses. IM, SubQ: 0.5 mL per dose for a total of 1 to 4 doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Not routinely recommended unless at increased risk of exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Immunization: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Poliovirus vaccine-na&iuml;ve (no previous IPV or OPV vaccine): IM, SubQ: Administer 0.5 mL per dose for a total of 3 doses given as follows: Two 0.5 mL doses administered at 1- to 2-month intervals, followed by a third dose 6 to 12 months later. If &lt;3 months, but at least 2 months are available before protection is needed, 3 doses may be administered at least 1 month apart. If administration must be completed within 1 to 2 months, give 2 doses at least 1 month apart. If &lt;1 month is available, give 1 dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previously vaccinated with at least at least 1 previous dose of OPV, &lt;3 doses of IPV, or a combination of OPV and IPV equaling &lt;3 doses: IM, SubQ: Administer at least one 0.5 mL dose of IPV. Additional doses to complete the series may be given if time permits.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Immunization for increased risk of exposure (completely vaccinated):</b> IM, SubQ: 0.5 mL as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211013\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IPOL: Type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL, 5 mL) [contains 2-phenoxyethanol, formaldehyde, calf serum protein, neomycin (may have trace amounts), streptomycin (may have trace amounts), and polymyxin B (may have trace amounts)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211001\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734135\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the U.S, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/ipv.html&amp;token=Jo+TJVXtdtuhdib4J4tH0wIdFfAoQY6fCoIuVJr+FoXRX/80yLOyozFsfsL3+Mw3XHD7ANvZUg1OBus0VA9g9w==&amp;TOPIC_ID=12967\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/ipv.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061206\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer IM or SubQ into midlateral aspect of the thigh in infants and small children; administer in the deltoid area to older children and adults; not for IV administration. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) should be used for the vaccination and firm pressure on the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211023\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store under refrigeration 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze. Protect from light</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061205\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Provide active immunity to poliovirus (FDA approved in ages &ge;6 weeks and adults)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; All infants and children (first dose given at 2 months of age) (CDC/ACIP 58[30] 2009)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Routine immunization of adults in the United States is generally not recommended. Adults with previous wild poliovirus disease, who have never been immunized, or those who are incompletely immunized may receive inactivated poliovirus vaccine if they fall into one of the following categories (CDC/ACIP [Prevots 2000]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Travelers to regions or countries where poliomyelitis is endemic or epidemic</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Health care workers in close contact with patients who may be excreting poliovirus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Laboratory workers handling specimens that may contain poliovirus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Members of communities or specific population groups with diseases caused by wild poliovirus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Incompletely vaccinated or unvaccinated adults in a household or with other close contact with children receiving oral poliovirus (may be at increased risk of vaccine associated paralytic poliomyelitis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12705163\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">IPV (inactivated poliovirus vaccine) may be confused with HPV (human papilloma virus vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">IPV (inactivated poliovirus vaccine) may be confused with PPD (purified protein derivative tuberculin test).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">IPV (inactivated poliovirus vaccine) may be confused with OPV (oral poliovirus vaccine, no longer licensed in the US, but still used in some other countries).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Poliovirus vaccine (inactivated) may be confused with tuberculin products. Medication errors have occurred when poliovirus vaccine (IPV) has been inadvertently administered instead of tuberculin skin tests (PPD). These products are refrigerated and often stored in close proximity to each other.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211037\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adverse events occurred with concomitant administration of DTP or DTaP vaccine and observed within 48 hours of injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Excessive crying (reported within 72 hours), fatigue, irritability (most common in infants 2 months of age)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site, swelling at injection site, tenderness at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (&gt;39&deg;C)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Agitation, anaphylactic shock, anaphylaxis, arthralgia, drowsiness, febrile seizures, headache, hypersensitivity reaction, lymphadenopathy, myalgia, paresthesia, seizure, skin rash, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211018\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any component of the vaccine, including 2-phenoxyethanol, formaldehyde, neomycin, streptomycin and polymyxin B; anaphylaxis or anaphylactic shock occurring within 24 hours of administration of 1 dose of vaccine; acute, febrile illness (excluding minor illness with or without low-grade fever).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211004\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polio infection: Patients with prior clinical poliomyelitis or incomplete immunization with oral poliovirus vaccine (OPV) may receive inactivated poliovirus vaccine (IPV).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune globulin: Immune response may be decreased in patients receiving immune globulin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression; may have a reduced response to vaccination. According to the manufacturer, patients with HIV infection, severe combined immunodeficiency, hypogammaglobulinemia, agammaglobulinemia, or altered immunity (due to corticosteroids, alkylating agents, antimetabolites, or radiation) may receive inactivated poliovirus vaccine (IPV). In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use of the minimum age and minimum intervals during the first 6 months of life should only be done when the vaccine recipient is at risk for imminent exposure to circulating poliovirus (shorter intervals and earlier start dates may lead to lower seroconversion). Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; 2-phenoxyethanol: Products may contain 2-phenoxyethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Calf serum protein: Products may contain calf serum protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Formaldehyde: Products may contain formaldehyde.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neomycin: Products may contain neomycin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polymyxin B: Products may contain polymyxin B.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Streptomycin: Products may contain streptomycin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (CDC/ACIP [Robinson 2017]). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299896\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211008\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12967&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2983218\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Animal reproduction studies have not been conducted. Although adverse effects of IPV have not been documented in pregnant women or their fetuses, vaccination of pregnant women should be avoided on theoretical grounds. Pregnant women at increased risk for infection and requiring immediate protection against polio may be administered the vaccine (CDC/ACIP [Prevots 2000]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13929247\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25318339\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As an inactivated virus vaccine, poliovirus vaccine induces active immunity against poliovirus types 1, 2, and 3 infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061209\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">As the global eradication of poliomyelitis continues, the risk for importation of wild-type poliovirus into the US decreases dramatically. To eliminate the risk for vaccine-associated paralytic poliomyelitis (VAPP), an all-IPV schedule is recommended for routine childhood vaccination in the US. Oral polio vaccine (OPV) is no longer distributed in the US; OPV is the vaccine of choice for global eradication in areas with continued or recent circulation of wild-type poliovirus, most developing countries where the higher cost of IPV prohibits its use or where inadequate sanitation necessitates an optimal barrier to wild-type virus circulation (CDC/ACIP [Marin 2017]). <i></i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral poliovirus vaccine (OPV), is not commercially available in the US, but has been stockpiled for use in the following special circumstances:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mass vaccination campaigns to control outbreaks of paralytic polio</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Unvaccinated children who will be traveling within 4 weeks to areas where polio is endemic or epidemic</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children of parents who do not accept the recommended number of vaccine injections; these children may receive OPV only for the third or fourth dose or both. In this situation, health care providers should administer OPV only after discussing the risk for VAPP with parents or caregivers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Currently, the primary risk for paralytic polio in US residents is through travel to countries where polio remains endemic or where polio outbreaks are occurring. Unvaccinated persons traveling to countries that use OPV should be aware of the risk caused by OPV and should consider polio vaccination prior to travel.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038772\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Imovax Polio (AR, BE, BG, CN, CZ, DK, EE, FI, HK, HN, HR, IL, IS, IT, KR, LT, LU, LV, MT, NO, PE, PH, PK, PY, RO, SK, TW, UY, VN);</li>\n      <li>Ipol (NZ);</li>\n      <li>Opvero (AE, KW, LB, QA, SA, TH);</li>\n      <li>Polio Salk &quot;Sero&quot; (AT);</li>\n      <li>Polprotec (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. <i>MMWR Recomm Rep</i>. 2009;58(30):829-830.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-pediatric-drug-information/abstract-text/19661857/pubmed\" target=\"_blank\" id=\"19661857\">19661857</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ipol (poliovirus vaccine inactivated) [prescribing information]. Swiftwater PA: Sanofi Pasteur Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-pediatric-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marin M, Patel M, Oberste S, Pallansch MA. Guidance for assessment of poliovirus vaccination status and caccination of children who have received poliovirus vaccine outside the United States. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(1):23-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-pediatric-drug-information/abstract-text/28081056/pubmed\" target=\"_blank\" id=\"28081056\">28081056</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prevots DR, Burr RK, Sutter RW, Murphy TV; Advisory Committee on Immunization Practices. &ldquo;Poliomyelitis Prevention in the United States: Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo; <i>MMWR Recomm Rep</i>, 2000, 49(RR-5):1-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-pediatric-drug-information/abstract-text/ 15580728 /pubmed\" target=\"_blank\" id=\" 15580728 \"> 15580728 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &quot;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&quot; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-pediatric-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-pediatric-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/poliovirus-vaccine-inactivated-pediatric-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12967 Version 92.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F211024\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F211025\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061202\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061195\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211013\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F211001\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734135\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061206\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F211023\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061205\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F12705163\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211037\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F211018\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F211004\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299896\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F211008\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2983218\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13929247\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F25318339\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1061209\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038772\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12967|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=poliovirus-vaccine-inactivated-drug-information\" class=\"drug drug_general\">Poliovirus vaccine (inactivated): Drug information</a></li><li><a href=\"topic.htm?path=poliovirus-vaccine-inactivated-patient-drug-information\" class=\"drug drug_patient\">Poliovirus vaccine (inactivated): Patient drug information</a></li></ul></div></div>","javascript":null}